AR093726A1 - A COMPOSITION THAT INCLUDES METFORMIN - Google Patents

A COMPOSITION THAT INCLUDES METFORMIN

Info

Publication number
AR093726A1
AR093726A1 ARP120100058A ARP120100058A AR093726A1 AR 093726 A1 AR093726 A1 AR 093726A1 AR P120100058 A ARP120100058 A AR P120100058A AR P120100058 A ARP120100058 A AR P120100058A AR 093726 A1 AR093726 A1 AR 093726A1
Authority
AR
Argentina
Prior art keywords
ligand
receptor
composition
group
composition according
Prior art date
Application number
ARP120100058A
Other languages
Spanish (es)
Inventor
R G Jones Christopher
S Fineman Mark
R A Beeley Nigel
r brown Martin
D Baron Alain
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Priority to ARP120100058A priority Critical patent/AR093726A1/en
Publication of AR093726A1 publication Critical patent/AR093726A1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición que comprende metformina, o una sal de la misma, adaptada para liberar dicha metformina o sal de la misma en una o más regiones del intestino de un sujeto. La composición además puede comprender un ligando del receptor quimiosensor que se selecciona del grupo que consiste de un ligando de un receptor de sabor dulce, un ligando de un receptor del gusto amargo, un ligando de un receptor de umami, un ligando de un receptor de grasas, un ligando del receptor de sabor ácido y un ligando de un receptor de ácidos biliares. Reivindicación 10: Una composición de acuerdo con cualquiera de las reivindicaciones 1 - 9, caracterizada porque la composición además comprende un ligando del receptor quimiosensor que se selecciona del grupo que consiste de un ligando de un receptor de sabor dulce, un ligando de un receptor del gusto amargo, un ligando de un receptor de umami, un ligando de un receptor de grasas, un ligando del receptor de sabor ácido y un ligando de un receptor de ácidos biliares. Reivindicación 14: Una composición de acuerdo con cualquiera de las reivindicaciones 1 - 10, caracterizada porque comprende además un agente antidiabético o antiobesidad. Reivindicación 15: Una composición de acuerdo con la reivindicación 11, caracterizada porque dicho agente antidiabético está seleccionado del grupo que consiste en tiazolidindionas, sulfonilureas, meglitinidas, biguanidas, un inhibidor de a-glucosidasa, un inhibidor de DPPIV y miméticos de incretina. Reivindicación 16: Una composición farmacéutica de acuerdo a la reivindicación 20, caracterizada porque dicho agente antiobesidad está seleccionado entre el grupo que consiste en fentermina, fenfluramina, sibutramina, rimonabant, topiramato, zonisamida bupropión, naltrexona, lorcaserina y orlistat.A composition comprising metformin, or a salt thereof, adapted to release said metformin or salt thereof in one or more regions of a subject's intestine. The composition may further comprise a chemosensor receptor ligand that is selected from the group consisting of a sweet taste receptor ligand, a bitter taste receptor ligand, a umami receptor ligand, a receptor ligand fats, an acid flavor receptor ligand and a bile acid receptor ligand. Claim 10: A composition according to any one of claims 1-9, characterized in that the composition further comprises a chemosensor receptor ligand that is selected from the group consisting of a ligand of a sweet-tasting receptor, a ligand of a receptor of the Bitter taste, a ligand of a umami receptor, a ligand of a fat receptor, a ligand of the acid taste receptor and a ligand of a bile acid receptor. Claim 14: A composition according to any of claims 1-10, characterized in that it further comprises an antidiabetic or anti-obesity agent. Claim 15: A composition according to claim 11, characterized in that said antidiabetic agent is selected from the group consisting of thiazolidinediones, sulfonylureas, meglitinides, biguanides, an a-glucosidase inhibitor, a DPPIV inhibitor and incretin mimetics. Claim 16: A pharmaceutical composition according to claim 20, characterized in that said anti-obesity agent is selected from the group consisting of phentermine, fenfluramine, sibutramine, rimonabant, topiramate, zonisamide bupropion, naltrexone, lorcaserin and orlistat.

ARP120100058A 2012-01-06 2012-01-06 A COMPOSITION THAT INCLUDES METFORMIN AR093726A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP120100058A AR093726A1 (en) 2012-01-06 2012-01-06 A COMPOSITION THAT INCLUDES METFORMIN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP120100058A AR093726A1 (en) 2012-01-06 2012-01-06 A COMPOSITION THAT INCLUDES METFORMIN

Publications (1)

Publication Number Publication Date
AR093726A1 true AR093726A1 (en) 2015-06-24

Family

ID=56117180

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100058A AR093726A1 (en) 2012-01-06 2012-01-06 A COMPOSITION THAT INCLUDES METFORMIN

Country Status (1)

Country Link
AR (1) AR093726A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111632033A (en) * 2020-06-08 2020-09-08 九江学院 Medicine composition for resisting carbapenem-resistant Klebsiella pneumoniae and preparation method and application thereof
CN114213426A (en) * 2021-11-18 2022-03-22 西北农林科技大学 Application of fructus crataegi extract and its compound in preparing herbicide

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111632033A (en) * 2020-06-08 2020-09-08 九江学院 Medicine composition for resisting carbapenem-resistant Klebsiella pneumoniae and preparation method and application thereof
CN114213426A (en) * 2021-11-18 2022-03-22 西北农林科技大学 Application of fructus crataegi extract and its compound in preparing herbicide

Similar Documents

Publication Publication Date Title
CR20180233A (en) OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS
UY37460A (en) 1,2,4-TRIAZOLONS WITH ANALATION IN 4 AND 5
MX2016012370A (en) Antimicrobial compositions containing cationic active ingredients.
CL2019000935A1 (en) Pharmaceutical composition, methods for treatment and uses thereof.
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
AR106505A1 (en) TREATMENT OF OLIGO-OVULATION RELATED TO HEPATIC ESTEATOSIS
NI201100025A (en) METHODS OF ADMINISTRATION OF TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS.
CL2011001306A1 (en) Antimicrobial composition comprising a soluble silver salt, an alkanolamide, and / or amino alcohol, a ph 6 or higher; cleansing composition comprising a surfactant, a soluble silver salt, an alkanolamide, and / or amino alcohol.
MX364800B (en) Improved long-acting tilmicosin and use thereof in the treatment of bovine respiratory disease complex (brdc) and in the dry cow period.
AR102777A1 (en) COMPOSITIONS OF ARNi AGAINST TMPRSS6 AND METHODS FOR USE
WO2015095735A3 (en) Vaccine compositions and uses thereof
PE20151746A1 (en) BICYCLE COMPOUNDS
MX2016014771A (en) Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use.
PE20150721A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING GEMIGLIPTIN AND METFORMIN, AND METHOD FOR THEIR PREPARATION
PE20170430A1 (en) ARYLHYDRAZIDES CONTAINING A FRACTION OF 2-PYRIDONE AS SELECTIVE ANTIBACTERIAL AGENTS
AR093726A1 (en) A COMPOSITION THAT INCLUDES METFORMIN
AR055562A1 (en) 1,3 OXAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
AR083423A1 (en) SUPPRESSION OF AN IMMUNE TYPE 1 HYPERSENSITIVITY RESPONSE WITH AN UN RELATED ANTIGEN
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
AR106559A1 (en) WATERPROOF SUSPENSION FOR ORAL ADMINISTRATION AND METHOD FOR PREPARATION
AR105111A1 (en) COMPOSITION FOR ADMINISTRATION OF ACTIVE AGENTS TO AN ANIMAL
PE20211787A1 (en) IMMUNOGENIC LHRH COMPOSITION AND USE OF LHRH IN PIGS
CL2016002721A1 (en) A 1,1'- (1,6-dioxo-1,6-hexanediyl) bis-d-proline prodrug
MX2020003697A (en) Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof.
AR092168A1 (en) PARENTERAL FORMULATIONS OF RASAGILINA

Legal Events

Date Code Title Description
FC Refusal